812 related articles for article (PubMed ID: 26806809)
21. Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer.
Zheng P; Zhang Y; Zhang B; Wang Y; Wang Y; Yang L
Biomed Pharmacother; 2018 Nov; 107():1064-1073. PubMed ID: 30257318
[TBL] [Abstract][Full Text] [Related]
22. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
Pandiella A; Morís F; Ocaña A; Núñez LE; Montero JC
Oncotarget; 2015 Oct; 6(32):32856-67. PubMed ID: 26439989
[TBL] [Abstract][Full Text] [Related]
23. Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer.
Liao MY; Kuo MY; Lu TY; Wang YP; Wu HC
Int J Oncol; 2015 Apr; 46(4):1788-800. PubMed ID: 25652097
[TBL] [Abstract][Full Text] [Related]
24. Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.
Simon N; Antignani A; Sarnovsky R; Hewitt SM; FitzGerald D
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075852
[TBL] [Abstract][Full Text] [Related]
25. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
27. EpCAM-targeted therapy for human hepatocellular carcinoma.
Ogawa K; Tanaka S; Matsumura S; Murakata A; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Tanabe M; Arii S
Ann Surg Oncol; 2014 Apr; 21(4):1314-22. PubMed ID: 24370904
[TBL] [Abstract][Full Text] [Related]
28. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
29. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
31. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
32. A Novel Immunotoxin Targeting Epithelial Cell Adhesion Molecule Using Single Domain Antibody Fused to Diphtheria Toxin.
Roshan R; Naderi S; Behdani M; Ahangari Cohan R; Kazemi-Lomedasht F
Mol Biotechnol; 2023 Apr; 65(4):637-644. PubMed ID: 36129635
[TBL] [Abstract][Full Text] [Related]
33. Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in Vivo.
Li HC; Xia ZH; Chen YF; Yang F; Feng W; Cai H; Mei Y; Jiang YM; Xu K; Feng DX
Cell Physiol Biochem; 2017; 43(5):1829-1840. PubMed ID: 29050003
[TBL] [Abstract][Full Text] [Related]
34. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
Sameni M; Tovar EA; Essenburg CJ; Chalasani A; Linklater ES; Borgman A; Cherba DM; Anbalagan A; Winn ME; Graveel CR; Sloane BF
Clin Cancer Res; 2016 Feb; 22(4):923-34. PubMed ID: 26432786
[TBL] [Abstract][Full Text] [Related]
35. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
37. Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
Chang CH; Wang Y; Li R; Rossi DL; Liu D; Rossi EA; Cardillo TM; Goldenberg DM
Cancer Res; 2017 Oct; 77(19):5384-5394. PubMed ID: 28819027
[TBL] [Abstract][Full Text] [Related]
38. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
39. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
Liao MY; Lai JK; Kuo MY; Lu RM; Lin CW; Cheng PC; Liang KH; Wu HC
Oncotarget; 2015 Sep; 6(28):24947-68. PubMed ID: 26317650
[TBL] [Abstract][Full Text] [Related]
40. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
